UroGen Pharma Ltd. (NASDAQ:URGN) Q1 2026 Earnings Call Transcript
UroGen Pharma Ltd. (NASDAQ:URGN) Q1 2026 Earnings Call Transcript May 6, 2026UroGen Pharma Ltd. beats earnings expectations. Reported EPS is $-0.47, expectations were $-0.48244.
Urogen Pharma Ltd. (URGN)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Kynam Capital Derrick Tang | 2,434,207 | $89,578,818 | +9% | 4.95% |
| 2. | Leucadia National Ian Cumming And Joseph Steinberg | 2,199,652 | $80,947,194 | 0.53% | |
| 3. | Point72 Asset Management Steve Cohen | 1,525,549 | $56,140,203 | 0.06% | |
| 4. | Opaleye Management James A. Silverman | 1,439,996 | $52,991,853 | +1% | 4.8% |
| 5. | SilverArc Capital Devesh Gandhi | 1,301,979 | $47,912,827 | -14% | 4.98% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $13.10 | 160 | $2,096.00 | 21,997 | 2021-11-18 | Filing | |
| $15.85 | 2,500 | $39,625.00 | 2,500 | 2021-05-17 | Filing | |
| $15.71 | 2,500 | $39,275.00 | 2,500 | 2021-05-17 | Filing | |
| $18.50 | 10,000 | $185,000.00 | 229,117 | 2020-12-14 | Filing | |
| $28.00 | 7,530 | $210,840.00 | 16,548 | 2019-11-21 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $42.92 | 871 | $37,383.32 | 59,882 | 2026-09-08 | Filing | |
| $42.54 | 1,519 | $64,618.26 | 53,141 | 2026-09-08 | Filing | |
| $47.05 | 60,677 | $2,854,852.85 | 59,086 | 2026-08-20 | Filing | |
| $40.00 | 10,000 | $400,000.00 | 119,763 | 2026-07-09 | Filing | |
| $35.01 | 10,000 | $350,100.00 | 129,763 | 2026-06-22 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 4,543,895 | $167,215,336 | 1.43% | |
| 2. | 3,201,461 | $117,813,765 | 0% | |
| 3. | 2,576,363 | $94,810,189 | 0.01% | |
| 4. | 1,685,719 | $62,034,564 | 0.03% | |
| 5. | 1,673,420 | $61,581,856 | 16.8% |
News See All
UroGen Pharma Ltd. (NASDAQ:URGN) Q4 2025 Earnings Call Transcript
UroGen Pharma Ltd. (NASDAQ:URGN) Q4 2025 Earnings Call Transcript March 2, 2026UroGen Pharma Ltd. beats earnings expectations. Reported EPS is $-0.53552, expectations were $-0.66.
UroGen Pharma (URGN) Closes Q3 2025 With $127.4 Million in Cash Amid Rising R&D Costs
UroGen Pharma Ltd. (NASDAQ:URGN) is one of the best small-cap biotech stocks to buy according to analysts. On November 6, 2025, UroGen Pharma Ltd.
10 Best Small-Cap Biotech Stocks to Buy According to Analysts
In this piece, we discuss the 10 Best Small-Cap Biotech Stocks to Buy According to Analysts. Small-cap biotech stocks are marking their latest resurgence, attracting renewed investor attention.
UroGen Pharma Ltd. (NASDAQ:URGN) Q3 2025 Earnings Call Transcript
UroGen Pharma Ltd. (NASDAQ:URGN) Q3 2025 Earnings Call Transcript November 6, 2025UroGen Pharma Ltd. beats earnings expectations. Reported EPS is $-0.69, expectations were $-0.72.
UroGen Pharma Ltd. (NASDAQ:URGN) Q2 2025 Earnings Call Transcript
UroGen Pharma Ltd. (NASDAQ:URGN) Q2 2025 Earnings Call Transcript August 9, 2025 Operator: Good day, and thank you for standing by. Welcome to the UroGen Pharma Second Quarter 2025 Earnings Call.
UroGen Pharma (URGN) Presented Real-World Study of JELMYTO at 2025 American Society of Clinical Oncology
UroGen Pharma Ltd. (NASDAQ:URGN) is one of the Stocks With Huge Catalysts on the Horizon. On June 2, UroGen Pharma Ltd.
10 Stocks With Huge Catalysts on the Horizon
In this article, we will look at the 10 Stocks With Huge Catalysts on the Horizon. The August 1 tariff deal is approaching; however, the market seems to have gotten used to the tariff headlines.
UroGen Pharma Receives FDA Approval for ZUSDURI for Recurrent Bladder Cancer
UroGen Pharma Ltd. (NASDAQ:URGN) is one of the best hot stocks to buy according to Wall Street analysts.
11 Best Hot Stocks to Buy According to Wall Street Analysts
On July 1, Ralph Schlosstein, Evercore's chairman emeritus and BlackRock's co-founder, joined 'Closing Bell Overtime' on CNBC to talk about his outlook for markets heading into the second half of the ...
Hedge Fund Resource Center